CARsgen Therapeutics Holdings Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zonghai Li

Chief Executive Officer (CEO)

CN¥2.1m

Compensación total

Porcentaje del salario del CEO	50.2%
Permanencia del CEO	3.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Zonghai Li en comparación con los beneficios de CARsgen Therapeutics Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥2m	CN¥1m	-CN¥748m
Sep 30 2023	n/a	n/a	-CN¥834m
Jun 30 2023	n/a	n/a	-CN¥920m
Mar 31 2023	n/a	n/a	-CN¥906m
Dec 31 2022	CN¥2m	CN¥1m	-CN¥892m

Compensación vs. Mercado: La compensación total ($USD287.77K) de Zonghai está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD406.02K).

Compensación vs. Ingresos: La compensación de Zonghai ha aumentado mientras la empresa no es rentable.

CEO

Zonghai Li (50 yo)

3.3yrs

Permanencia

CN¥2,084,000

Compensación

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zonghai Li	Co-Founder	3.3yrs	CN¥2.08m	sin datos
Huamao Wang	Co-Founder	3.3yrs	CN¥2.11m	sin datos
Hua Jiang	Executive Director	1.8yrs	CN¥1.39m	sin datos
Hong Ma	Senior Vice President of Clinical Development	no data	sin datos	sin datos
Leigh Hsu	Senior Vice President of Business Development	no data	sin datos	sin datos
Raffaele Baffa	Chief Medical Officer	2.2yrs	sin datos	sin datos
Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	1.7yrs	sin datos	sin datos
Wing Yat Lui	Company Secretary	3.3yrs	sin datos	sin datos

2.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2171 se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zonghai Li	Co-Founder	6.3yrs	CN¥2.08m	sin datos
Huamao Wang	Co-Founder	5.8yrs	CN¥2.11m	sin datos
Hua Jiang	Executive Director	1.8yrs	CN¥1.39m	sin datos
Ronggang Xie	Non-Executive Director	3.8yrs	sin datos	sin datos
Xiangke Zhao	Independent Non-Executive Director	less than a year	CN¥80.00k	sin datos
Bingsen Guo	Non-Executive Director	5.8yrs	sin datos	1.55% CN¥ 49.2m
Guangmei Yan	Independent Non-Executive Director	3yrs	CN¥222.00k	sin datos
Huaqing Guo	Non-Executive Director	3.8yrs	sin datos	0.30% CN¥ 9.4m
Wen Zhou	Independent Non-Executive Director	less than a year	sin datos	sin datos

3.8yrs

Permanencia media

47yo

Promedio de edad

Junta con experiencia: La junta directiva de 2171 se considera experimentada (3.6 años de antigüedad promedio).

CARsgen Therapeutics Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Non-Executive Director recently bought HK$903k worth of stock

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Recent updates

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New major risk - Share price stability

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad